ACIC

Rooted in the North American pharmaceutical market since 1968, ACIC has built its reputation on guiding active pharmaceutical ingredients from early sourcing through to commercial production. The company was established by Luciano Calenti, who arrived in Canada to help create one of the country's first synthetic antibiotic manufacturing facilities, with an initial focus on antibiotics such as amoxicillin. ACIC subsequently developed exclusive partnerships with European manufacturers to supply and distribute APIs, ensuring adherence to both FDA and Health Canada regulatory requirements from the outset.

Over the decades, the company expanded its technical capabilities significantly. ACIC opened its first R&D laboratory dedicated to chemical synthesis and later constructed a synthesis plant in Brantford, Canada, supporting both research and commercial-scale production. That facility received approval from the US FDA and Health Canada's Therapeutic Products Directorate, reflecting the dual-market compliance that has characterised ACIC's approach throughout its history.

The company's work has spanned APIs, injectables, and the development of joint venture manufacturing facilities across North America. Today ACIC positions itself as an integrator of pharmaceutical equipment solutions alongside its pharmaceutical services, operating under the guiding principle of taking products from molecule to market through innovation. This combination of long-standing regulatory experience, synthesis infrastructure, and strategic manufacturer partnerships places ACIC within the broader contract and specialist services segment of the North American pharmaceutical industry.

Further information is available at acic.com.